The Inherent Risks Associated With Newly Traded Biopharmaceutical Firms by NC DOCKS at Appalachian State University & Williams, David
Archived version from NCDOCKS Institutional Repository http://libres.uncg.edu/ir/asu/ 
The Inherent Risks Associated With Newly 
Traded Biopharmaceutical Firms
By: David R. Williams and Trent J. Spaulding
Abstract
Here, we provide a comprehensive study related to the risks of all biopharmaceutical firms going public in the 
USA between 1996 and 2015. We found 355 firms that met our requirements for being in the sector that focuses 
on creating drugs for humans. Collectively, these firms spent approximately US$86.9 billion on research and 
development (R&D) during this time. They also lost approximately US$69.3 billion in combined net income. We 
also examine the de-listing of these firms from a public market, their number of collaborators at the initial public 
offering (IPO), and estimate the percentage ownership by other biopharmaceutical firms at the IPO.
Williams, D.R. and Spaulding, T.J. (2018). "The inherent risks associated with newly traded biopharmaceutical 
firms." Drug Discovery Today. 23(9): 1680-1688. Publisher version of record available at: https://
www.sciencedirect.com/science/article/pii/S1359644618300515
REVIEWS Drug Discovery Today Volume 23, Number 9  September 2018
The inherent risks associated with
newly traded biopharmaceutical firms
David R. Williams and Trent J. Spaulding
Appalachian State University, Beaver College of Health Sciences, 261 Locust Street, Boone, NC 28608, USA
Here, we provide a comprehensive study related to the risks of all biopharmaceutical firms going public in the 
USA between 1996 and 2015. We found 355 firms that met our requirements for being in the sector that focuses 
on creating drugs for humans. Collectively, these firms spent approximately US$86.9 billion on research and 
development (R&D) during this time. They also lost approximately US$69.3 billion in combined net income. 
We also examine the delisting of these firms from a public market, their number of collaborators at the initial 
public offering (IPO), and estimate the percentage ownership by other biopharmaceutical firms at the IPO.
 
Introduction
The biopharmaceutical sector is characterized by high levels of risk
because of the scientific uncertainty surrounding industry endea-
vors and the unusually intensive R&D (see Glossary) nature of the
enterprise [1,2]. We use the term ‘biopharmaceutical sector’ to
mean the sector comprising the merging biotechnology and phar-
maceutical industries. Although many large, established biophar-
maceutical firms, representing most of the market capitalization of
the industry, are able to achieve normal profits over the long run
[3], this is not the case with most firms in the sector. The most
common type of biopharmaceutical firm, numbering in the hun-
dreds or thousands, is the small firm, engaged in R&D but with no
drug product on the market. Yet, these firms are an important part
of the wider industry landscape [4].
Biopharmaceutical firms are largely equity financed [5]. The
equity financiers of private biopharmaceutical firms include sci-
entist-entrepreneurs, venture capitalists, and other biopharmaceu-
tical firms [6]. They are part of a growing ecosystem in the
biopharmaceutical industry, where new smaller firms and larger
publicly traded firms are developing symbiotic relationships. For
example, it has been reported that GlaxoSmithKline is investing
nearly half of its R&D efforts into academia and small biotechnol-
ogy firms [7]. Many scientist-entrepreneurs would prefer to main-
tain the control associated with a privately held firm [8,9].Corresponding author: Williams, D.R. (willimsdr@appstate.edu)
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bringing a chemical-based or biological product to market [11,12],
and the low probability of developing a profitable product [13,14],
they are unable to achieve this goal of remaining private, even
with funding from large biopharmaceutical firms. To increase their
funds and mitigate their risks, many firms undergo an IPO, itself a
timely and expensive process [15,16]. Much research has been
done on the success rates of individual drugs and therapeutic
classes, yet much remains unknown about the collective activity
surrounding firms that have gone public over time.
The IPO is the process by which a firm sells its securities or stock
for the first time on an open, public market. A public market is a
place or system that allows for the exchange of the stock of a firm
between entities and individuals, such as the Nasdaq stock market
or the New York Stock Exchange [17]. Private firms undertake an
IPO for several reasons, including (i) raising money for internal
growth; (ii) diversification into related and unrelated areas; (3)
raising public awareness of the firm and its products; (4) increasing
financial transparency; and (5) survival [18,19]. For many firms, an
IPO represents the most efficient means to raise capital.
Various recent academic and practitioner-oriented studies have
examined biopharmaceutical IPO activity. For example, Williams
and Young, studying biopharmaceutical IPOs from 1996 to 2005,
found that, for those firms that survived, their stock price rose only
7.7% [20]. Booth showed that the average investor in biopharma-
ceutical IPOs from 2003 to 2007 lost money in terms of the returnen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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GLOSSARY
Annual report A document used by most publicly traded
firms to disclose corporate information to their shareholders
Collaborations Agreements among entities in which each
party commits complementary resources or capabilities to
achieve a common set of objectives. They can include joint
ventures, equity-based alliances, or licensing arrangements
Delisting When the stock of a firm ceases to trade on an
open, public market
Initial public offering (IPO) Process by which a firm sells its
stock for the first time on an open, public market, such as the
New York Stock Exchange or Nasdaq. ‘IPO’ can also refer to
the firm itself
Net income The profit of a firm in a given fiscal period. It
comprises total revenues earned in the period less total
expenses incurred in the period. When revenues exceed
expenses, the firm has a net profit. When expenses exceed
revenues, the firm has a net loss
Prospectus A document required by the SEC providing
details about the securities of a specific firm offered for sale
to the public
Research and development (R&D) Investigative activities a
firm conducts to lead to the development of new products
and procedures or to improve existing products and
procedures
R&D intensity Expenditures by a firm on its R&D efforts
divided by the its sales or revenues. Revenues can include
monies received from collaborations
Standard industrial classification (SIC) codes Four-digit
codes that categorize companies by the type of business
activities in which they engage
Venture capital Equity or equity-linked investment in
privately held companies or publicly traded companies,
where the investor is a financial intermediary who typically
invests the monies of other individuals or entities and often












on their invested capital [21]. Carter et al., studying biopharma-
ceutical IPOs from 2010 to 2014, found that small-molecule firms
comprised the majority of biopharmaceutical firms going public
[22]. Comparing two similar times of high biopharmaceutical IPOTABLE 1
Firm years by year and SIC code
SIC code Year
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 20
2833 1 1
2834 10 17 16 20 44 48 48 50 67 72 82
2835 2 3 3 2 3 3 3 3 3 2 2
2836 3 9 9 9 11 13 13 15 17 17 19
3826 1 1 1 1 4 4 4 4 3 4 4
3829 1 1 1 1 2 2 1




8731 1 2 4 5 14 11 10 8 8 8 9
8734 1 1 1 1 1 1 1
Total 19 35 34 38 79 82 81 83 102 109 12
% 1 2 2 2 4 4 4 4 5 5 6activity, McNamee and Ledley found biopharmaceutical IPOs
between 2012 and 2014 raised significantly less monies on average
than their counterparts did in 1999 and 2000 [23]. Given this,
several scholars have questioned whether the current business
model of biopharmaceutical research and development, which
includes the IPO process, is sustainable [24,25].
Here, we provide a comprehensive analysis over a 20-year period
of key areas related to the financing of biopharmaceutical IPOs,
which has not been previously undertaken. The trade press has
made much of the relatively recent success of a handful of bio-
technology firms, such as Amgen and Genentech, ignoring much
of the uniqueness of their success. To better understand activity in
this market, we analyzed the Security & Exchange Commission’s
(SEC) filings for all biopharmaceutical firms primarily engaged in
the development of human drugs or their complements that went
public between 1996 and 2015. Our interest was in understanding
the total collective amount spent by the firms on R&D, their
profitability, collaborative arrangements, and delisting from a
public market, because this is a growing sector of the biopharma-
ceutical market that is receiving increased attention from biophar-
maceutical firms, investors, policy makers, and others.
Approach
The names of potential biopharmaceutical firms were collected
from various Internet sources, including but not limited to:
biospace.com, hoovers.com, ipomonitor.com, and SEC.gov. Here,
the firms are presented as grouped by standard industrial classifi-
cation (SIC) codes, which is a common practice in the business
literature. Other studies include different SIC codes, firm types (i.
e., nonholding companies, etc.), and IPO dates (i.e., date of
prospectus compared to date stock first offered), and offer price
floors for inclusion in their studies, which results in different
counts for the number of firms going public and other results.
Here, we exclude firms primarily engaged in products created for
agriculture (i.e., seeds companies) and animals regardless of SIC
codes. For most firms, individual SEC filings were inspected to
ensure that the firms were engaged in the biopharmaceutical
segment. External experts in the biopharmaceutical arena wereTotal %
06 2007 2008 2009 2010 2011 2012 2013 2014 2015
2 0
97 81 79 84 86 89 106 143 168 1407 68
2 2 1 1 1 36 2
19 16 14 13 11 10 14 22 28 282 14
4 4 3 5 5 5 5 6 5 73 4
1 1 1 1 1 1 1 1 1 18 1
4 3 3 3 3 3 3 4 6 45 2
1 1 1 1 1 1 1 2 3 14 1
1 1 1 1 1 1 1 1 1 11 1
1 1 1 1 1 1 2 4 6 20 1
8 7 6 7 8 7 6 7 6 142 7
1 1 1 1 11 1
4 139 118 111 117 117 118 139 191 225 2061 100
7 6 5 6 6 6 7 9 11 100
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BOX 1
SIC codes for the firms in the study
2833: Medicinal Chemicals and Botanical Products
2834: Pharmaceutical Preparations
2835: In vitro and In vivo Diagnostic Substances
2836: Biological Products, Except Diagnostic Substances
3826: Laboratory Analytical Instruments
3829: Measuring and Controlling Devices, Not Elsewhere Classified
3841: Surgical and Medical Instruments and Apparatus
3842: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
7389: Business Services, Not Elsewhere Classified
8071: Medical Laboratories
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EENalso consulted as to which firms should be included or excluded
from the study. Firms occasionally changed SIC codes in their
filings. We attempted to use the most appropriate code. Dates of
IPOs for the firms were found in the above Internet sites, the SEC
filings of the firms, EdgarPro IPO, yahoo.finance.com, or ipo.
findthecompany.com.
Financial data were collected from the annual reports of each
firm (i.e., 10K forms). Firms are required by the SEC to file annual
reports specifying particular information related to the financial
condition of the firm. Financial data were electronically collected
or ‘scraped,’ with each field in the data set being individually
examined for missing or abnormal results. When an issue was
identified with the data collected through scraping, the research-
ers individually reviewed the SEC filing itself and corrected any
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TABLE 2
R&D intensity by year and SIC code
Year Firm years Mean by firm year Median by firm year SIC Firm years Mean by firm year Median by firm year
1996 18 4.08 1.51 2833 2 0.06 0.06
1997 33 5.99 1.89 2834 1131 38.04 2.02
1998 29 8.40 2.16 2835 34 76.74 3.14
1999 33 7.27 2.00 2836 252 84.09 2.93
2000 70 53.62 2.48 3826 73 1.68 0.24
2001 74 49.31 2.74 3829 18 0.74 0.69
2002 73 55.30 2.58 3841 44 38.55 1.55
2003 74 6.98 1.93 3842 5 0.26 0.00
2004 93 20.93 2.38 7389 8 0.22 0.27
2005 100 46.31 2.19 8071 20 2.55 0.26
2006 115 26.05 2.40 8731 132 5.62 1.71
2007 119 34.02 1.81 8734 11 0.30 0.03
2008 102 172.89 1.95 Total 1730 40.14 1.83
2009 99 34.68 1.37
2010 101 23.52 1.07
2011 99 36.22 0.98
2012 95 32.49 1.26
2013 113 31.87 1.73
2014 134 21.46 1.89
2015 156 41.83 2.13












quarter of 2016, with an examination of the continuation of filing
by the firm with the SEC occurring into mid-January of 2017. Here,
the data are presented as inflation-adjusted. An Internet US infla-
tion calculator was used to adjust these data based on the con-
sumer price index, and these data were calculated on an annual
basis (and, thus, are not as precise as the other data reported) using
means and total amounts. Data related to the number of strategic
partners or collaborators, and ownership interest of other biophar-
maceutical firms were individually collected from the prospectus
of each firm; all data of these types were pre-IPO. Data for colla-
borations were estimates. We defined collaborations as being
between the IPO and other biopharmaceutical firms (i.e., not
universities or government agencies). The prospectus of a firm
typically has a collaboration section, which is where data for this
variable are usually found. When this section was absent, a word
search using ‘collaboration’, ‘strategic alliances’, and
‘partnerships’ was performed. At times, the prospectus language
was not specific as to the number of collaborators. We used our
best efforts to estimate these numbers based on the given infor-
mation in the prospectus.
The ownership interest was derived from the principal stock-
holder section of the prospectus. Ownership interest occurs before
the IPO (i.e., before IPO dilution of ownership). The ownership of
biopharmaceutical firms was determined if the biopharmaceutical
firm was owned directly or through a biopharmaceutical firm-
owned venture capital firm (e.g., Amgen Ventures or Lilly Ven-
tures). Names of biopharmaceutical-controlled venture capital
firms were compared with Pratt’s Guide to Venture Capital [26],
GEN’s Top 20 Corp Venture Capital Funds [27], and Internet
searches. We viewed survival as a firm filing an annual report
(10K) in 2015. For those firms that did not survive, other SEC
filings (and Internet searches) were read to determine the reasonfor this (e.g., mergers and acquisitions, or financial distress). We
used data from the National Venture Capital Yearbook [28] and Jay
Ritter’s Internet site [29] to derive the percentage of biopharma-
ceutical IPOs compared with all IPOs.
Overall, 355 biopharmaceutical firms went public from 1996
through 2015, representing 2061 firm years (Table 1). Firm
years represent the collective life of a firm while it is publicly
traded (excluding over-the-counter trading). We often calcu-
lated the means and medians based on firm years, because this
is a good way of showing entry and exit from the market. Table
1 shows the number of firm years by year and SIC code. These
355 biopharmaceutical firms represent 9% of all firms going
public in the USA regardless of industry [28,29]. We focus on
the three largest SIC codes by firm years: 2834, 2836, and 8731.
SIC code 2834 (pharmaceutical preparations) represents 68.0%
of all firm years. SIC code 2836 (biological products) represents
13.7% of all firm years, and SIC code 8731 (Services-Commer-
cial Physical & Biological Research) represents 6.8% of all firm
years. Box 1 lists the description of all SIC codes used in the
study. Firm years peaked in 2007 and then again in the latter
years of the study.
Research and development investment
Most firms in this study were drug or therapy research and devel-
opment firms, as opposed to complements in this industry. Over-
all, the 355 firms spent US$86.9 billion on R&D during the 20-year
period. Figure 1 depicts the mean, median, and R&D expenditures
by year. Table S1 in the Supplemental information online lists
R&D spend by year and SIC codes. R&D spending fairly closely
followed firm years. The 355 firms spent US$244.2 million per firm
or US$42.4 million per firm year on average. The overall median
was US$26.4 million per firm year.www.drugdiscoverytoday.com 1683
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EENFirms in SIC code 2834 spent US$62.1 billion over the 20-year
period or US$44.2 million per firm year on average. Firms in SIC
2836 spent US$12.6 billion over the 20-year period or US$44.6
million per firm year on average. Firms in SIC code 8731 spent US
$5.1 billion over the 20-year period or US$43.1 million per firm
year on average. In terms of mean and median by firm year, R&D
expenditures peaked in 2008, with firms spending US$51.3 million
on average. Perhaps because of the recession, mean, median, and
total R&D spending declined to pre-2008 levels in 2009 and slowly
rose over the ensuing years. From 2008 to 2009, total R&D expen-
ditures declined by 28%. By 2015, the mean amount spent on R&D
was nearing the 2008 level; however, the total R&D spent in 2015
was almost US$11 billion or an 82% increase from the 2008 level.
In total US dollars, R&D spending in 2015 was approximately 60
times more than in 1996. When adjusted for inflation to 1996 US1684 www.drugdiscoverytoday.comdollars, total R&D spending in 2015 was nearly US$7.3 billion or
40 times more than in 1996. When 2015 total R&D US dollars were
inflation-adjusted to 1999 levels (i.e., the first year that total R&D
spending exceeded US$1 billion dollars), then the total R&D
spending in 2015 was over five times the total amount spent in
1999.
An important financial indicator for technology industries is
R&D intensity [30–33]. R&D intensity is typically calculated by
dividing R&D expense by revenue. For many firms, including
many IPOs, revenue is derived from the selling of goods and/or
services to an end-user. For biopharmaceutical IPOs directly in-
volved with creating drugs and therapeutics, this is seldom the
case. Excluding the financing from owners (which can be substan-
tial and goes through multiple rounds) [34,35], revenues for many
biopharmaceutical firms at this stage are derived from collabora-
Drug Discovery Today Volume 23, Number 9  September 2018 REVIEWS
TABLE 3
Continued trading by year and SIC code
Year All firms (N = 355) SIC All firms (N = 355) Firms with IPO on or before 2012
(N = 220)
No. of firms Mean surviving No. of firms Mean surviving No. of firms Mean surviving
1996 19 0.32 2833 1 0.00 1 0.00
1997 16 0.31 2834 253 0.66 152 0.47
1998 4 0.00 2835 5 0.20 4 0.00
1999 8 0.63 2836 49 0.57 28 0.25
2000 44 0.36 3826 6 0.83 5 0.80
2001 6 0.33 3829 2 0.50 2 0.50
2002 4 0.00 3841 8 0.75 5 0.60
2003 7 0.00 3842 3 1.00 1 1.00
2004 22 0.32 7389 1 1.00 1 1.00
2005 13 0.38 8071 6 1.00 1 1.00
2006 21 0.48 8731 20 0.30 19 0.26
2007 18 0.44 8734 1 0.00 1 0.00




















tive agreements [36,37] or not at all. Total revenue for the 2064
firm years was US$63.4 million per firm year on average. Interest-
ingly, a few firms reported negative revenue, which is derived from
collaboration loss (and is different from collaboration expense). A
significant portion of firms also reported having no revenue at all,
with many firms noting they were a ‘development-stage
company’.
As Table 2 suggests, the R&D intensity of this segment was high.
Overall, for those firms with revenue (firm years 51 730) the R&D
intensity was 40.1 per firm year (median 1.8). This means that, for
the average firm, for every US$1 received in revenue, it was
spending US$40 dollars on R&D. Firms in SIC code 2834 had an
average R&D intensity of 38.1 per firm year. Firms in SIC code 2836
had an average R&D intensity of 84.1 per firm year. Firms in SIC
code 8731 had an average R&D intensity of 6.3 per firm year. R&D
intensity peaked in 2008 at 172.9. As reference points, the Nation-
al Science Foundation noted that R&D intensity in 2014 for all US
industries was 0.035, and 0.134 for all US pharmaceutical firms
[38].
IPO firm profitability
Relatively young firms tend to be unprofitable and this is particu-
larly true for biopharmaceutical firms that have gone public [10].
The 355 firms in the study collectively lost US$69.3 billion in net
income. When this was adjusted for inflation to 1996 US dollars,
this represents a total net loss of US$52.1 billion. This translates to
the 355 firms losing on average US$195.4 million per firm or US$33.6 million per firm year. If one compares 2015 inflation-ad-
justed mean or median net income to that in 2008, then one sees
US$40.6 million lost on average in 2015, comparable to that in
2008. The 355 firms had a median net loss of US$26.7 million per
firm year. Of the 2061 firm years, only 245 firm years (or 11.9%)
had positive net incomes and two firm years reported breaking
even. Broadly speaking, 88% of the time, the firms under study lost
money. For most biopharmaceutical firms, sustained losses are the
norm. Of the three SIC codes with the most firms and firm years,
firms within SIC code 2834 proportionally lost the most money at
US$48.4 billion in total or US$34.5 million per firm year. This was
followed by firms within SIC code 2836 losing US$12.1 billion in
total or US$42.8 million per firm year. Firms within SIC code 8731
lost US$3.8 billion in total or US$26.9 million per firm year.
Figure 2 illustrates the mean, median, and total net income of
the firms by year. Losses by year initially peaked in 2008. This
lagged by 1 year the peak year (2007) for R&D total spend, which is
reasonable. When adjusted for inflation to 1996 US dollars, this
represent a net loss of US$28.3 million per firm year or more than a
fivefold increase from 1996. Similarly, adjusting for inflation to
1996 US dollars, total net loss represents US$3.7 billion in 2008.
Net losses peak again in 2015, with the average firm losing US$44.7
million per firm year or US$10.1 billion total for the year or US$6.7
billion when adjusted for inflation to 1996 US dollars. Comparing
Fig. 1 on R&D spending and Fig. 2 (and the tables in the Supple-
mental information online) on net income, one can see the
general trend of both spending and net loses increasing up towww.drugdiscoverytoday.com 1685
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TABLE 4
Estimate of collaborators before IPO by year and SIC
Year All Firmsa Only Firms with
collaboratorsb
Total collaborators SIC All firmsa Only firms with
collaboratorsb
Total collaborators
Firms Est. mean Firms Est. mean Firms Est. mean Firms Est. mean
1996 18 1.89 15 2.27 34 2833 1 2.00 1 2.00 2
1997 16 3.06 13 3.77 49 2834 252 1.77 172 2.60 447
1998 4 1.75 3 2.33 7 2835 5 1.20 2 3.00 6
1999 8 2.50 7 2.86 20 2836 49 2.22 38 2.87 109
2000 44 2.64 37 3.14 116 3826 6 2.00 5 2.40 12
2001 6 2.83 5 3.40 17 3829 2 0.50 1 1.00 1
2002 4 1.00 3 1.33 4 3841 8 1.38 5 2.20 11
2003 7 0.71 3 1.67 5 3842 2 3.00 1 6.00 6
2004 22 1.68 18 2.06 37 7389 1 0.00 – – 0
2005 13 1.54 6 3.33 20 8071 6 0.67 3 1.33 4
2006 21 3.33 19 3.68 70 8731 20 2.90 16 3.63 58
2007 18 1.50 9 3.00 27 8734 1 4.00 1 4.00 4
2008 0 – 0 – – Total 353 1.87 245 2.69 660
2009 2 0.50 1 1.00 1
2010 14 1.64 10 2.30 23
2011 9 2.00 5 3.60 18
2012 12 1.58 9 2.11 19
2013 29 2.48 21 3.43 72
2014 62 1.26 39 2.00 78
2015 44 0.98 22 1.95 43
Total 353 1.87 245 2.69 660
aN = 353.








EENthe financial crisis of 2008, falling sharply in 2009, and then
slowing rising back to 2008 levels in 2015.
Delisting
Of the firms in the study, 63% continued to file an annual report
with the SEC in 2015. However, because firms in 2013, 2014, and
2015 represent a significant percentage of all 355 firms, the data are
somewhat skewed. If we eliminate firms going public after 2012,
only 43% continued to file an annual report in 2015, with 84% of
these operating at a net loss in 2015. Table 3 depicts the percentage
of firms that continued to remain publicly traded by year and SIC
code.
To further examine the data, we inspected firms that continued
to file annual reports 10, 5, and 3 years at different segments in
time. When examining firms that filed their first annual report in
2006 or before and continued to file annual reports over the
following 10 years, we found that 70 out of 164 firms (42.7%)
continued to file annual reports for the following 10 years. This
was consistent with our findings presented in Table 3. For these
same firms, 123 out 164 firms (75.0%) continued to file annual
reports for 5 years or more, and 141 out of 164 firms (86.0%)
continued to file annual reports for 3 years or more. For firms that
filed their first annual report in 2010 or before, we found that 148
of 199 firms (74.4%) continued to file for 5 years, and 172 out of
199 firms (86.4%) also filed annual reports for 3 years or more.1686 www.drugdiscoverytoday.comWhen we examined firms that filed their first annual report in
2012 or before and continued to file annual reports for 3 years, we
found 192 out of 220 firms (87.3%) survived for 3 years. Broadly
speaking, we can say that there is a fairly consistent decline in the
number of firms continuing to file annual reports over the follow-
ing 3- or 5-year period. This is true whether we examine firms at the
beginning of our 20-year study period or at the end.
Collaborations
A series of studies have shown the importance of strategic alliances
and other forms of collaboration to the young biopharmaceutical
firm [39–42]. Reasons for strategic alliance formation among bio-
pharmaceutical firms include to: (i) reduce uncertainty, particu-
larly technological uncertainty; (ii) transfer technology from one
firm to another; (iii) facilitate technology exchange between firms;
(iv) reduce the risks and costs of R&D; (v) learn from other firms;
(vi) provide legitimacy; and (vii) gain access to facilities [41].
Strategic alliances can take several forms. These include: (i) tech-
nology development alliances, which are design to expand tech-
nology know-how between firms; (ii) commercialization alliances,
which are designed to expand the manufacturing and marketing
capabilities of a firm; and (iii) financial alliances, which allow a
firm to pursue technological and commercialization strategies
[43,44]. Among small firms, alliance experience might initially
encourage a firm to go public rather than be acquired [43].
Drug Discovery Today Volume 23, Number 9  September 2018 REVIEWS
TABLE 5
Estimate of biopharmaceutical ownership before IPO by year and SIC
Year All firmsa Firms with
biopharmaceutical ownersb
SIC All firmsa Firms with
biopharmaceutical ownersb
Est. Mean Max. Est. Mean Median Est. Mean Max. Est. Mean Median
1996 19 11.11 47 10 21.11 19.05 2833 1 0.00 0.00 – – –
1997 16 11.31 60 6 30.17 22.00 2834 251 8.77 100.00 109 20.19 14.50
1998 4 26.00 80 3 34.67 16.00 2835 5 4.73 23.66 1 23.66 23.66
1999 8 11.75 47 3 31.33 24.00 2836 49 11.02 80.00 23 23.48 17.00
2000 44 2.89 19 13 9.78 9.00 3826 6 13.01 47.00 3 26.02 22.50
2001 6 18.00 83 3 36.00 19.00 3829 2 0.00 0.00 – – –
2002 4 67.25 100 4 67.25 65.50 3841 8 4.13 18.00 2 16.50 16.50
2003 7 3.86 20 2 13.50 13.50 3842 3 0.00 0.00 – – –
2004 22 8.27 60 10 18.20 10.50 7389 1 0.00 0.00 – – –
2005 13 3.85 16 4 12.50 12.00 8071 6 1.50 9.00 1 9.00 9.00
2006 21 4.33 17 8 11.38 10.50 8731 20 4.30 29.00 7 12.29 8.00
2007 17 5.41 36 5 18.40 17.00 8734 1 5.00 5.00 1 5.00 5.00
2008 0 – – 0 – – Total 353 8.43 100 147 20.24 15.00
2009 2 48.55 97 1 97.10 97.10
2010 14 6.61 28 7 13.22 12.50
2011 9 1.12 10 1 10.10 10.10
2012 12 14.00 98 4 42.00 32.10
2013 29 7.58 29 14 15.70 15.05
2014 62 10.26 45 35 18.17 16.40
2015 44 4.90 40 14 15.41 13.60
Total 353 8.43 100 147 20.24 15.00
aN = 353.












Table 4 shows an estimate of the number of collaborators
between a firm and other biopharmaceutical firms (not universi-
ties) before the IPO by year and SIC code for all firms in the study.
This is an estimate based on information clearly stated in the
prospectus as an arrangement that is a collaboration, alliance, or
partnership (with the firm stating it as such), and on a count of the
number of collaborations (and not the US dollar amount or a
qualitative measure of the collaboration). An in-licensing arrange-
ment can be a collaboration (or not) depending on whether the
firm declared it as such. The year depicts the first annual report.
As can be seen, 353 firms had usable data. Given the almost
routine losses experienced by these firms on an annual basis,
continuous R&D expenditures would be difficult for many without
the support of larger established firms, either through working
partnerships or some sort of financial backing. Of the 353 firms,
there were 660 total collaborators for a mean of 1.9 collaborators
per firm. There were 245 IPOs that reported collaborations (or 108
IPOs without reported collaborators). Of these 245 IPOs, the mean
was 2.7 collaborators per IPO.
Table 5 shows the percentage ownership interest by biophar-
maceutical firms prior to the IPO by year and SIC code. The results
show an average percentage ownership of 8.4% for all firms and
20.2% for those that have biopharmaceutical ownership. These
data come from the prospectus of each firm.Concluding remarks
The development of innovative drugs and therapies remains risky
and rife with failure [45,46], yet investors and scientists remain
optimistic about the therapeutic and financial potential of their
efforts. Much of the trade press focuses on the success (and
subsequent cost of drugs) of a few firms. Our results, taken togeth-
er, confirm that the biopharmaceutical IPO market remains a R&D
intensive market fraught with inherent risks. For every successful
firm, there are hundreds, if not more, of small public (and private)
firms that spend billions of dollars seeking to create drugs and
therapies to improve individuals’ lives, yet might never see a profit
or survive.
Specifically, the data in our study show that these firms absorb
high financial losses while making large R&D outlays in the quest
for new drug products. Cumulatively, these firms spent US$86.9
billion on R&D during this time. They also lost US$69.3 billion in
combined net income during this period. This financing in part
was borne by other biopharmaceutical firms. For the IPOs that
received financing from other biopharmaceutical firms, this own-
ership investment represented 20% of the value of the firm at the
time of the IPO. Clearly, multiple sources of financing are required
for these firms to continue to invest in R&D at this rate.
Demonstrating perhaps most vividly the uncertain prospect of
firms trying to find success through R&D, of the 355 firms thatwww.drugdiscoverytoday.com 1687








EENunderwent an IPO, only 63.4% survived to file an annual report
(10K) with the SEC in 2015. It is possible that firms that have
completed an IPO over the past few years have not had sufficient
time for us to judge their prospect of survival. However, the track
record of firms continuing to file annual reports over the course of
our study is consistent. Over less than a decade’s time, most firms
in our study ceased to trade on a public market. Specifically, we
found that, if one excludes firms that went public after 2012, then
only 42.7% of the firms that went public between 1996 and 2012
continued to trade their stock on a public market in 2015, with
84% of these firms continuing to lose money in 2015. For firms
with 10 years or more of filings, they averaged 9.5 years before their1688 www.drugdiscoverytoday.comfirst year of profitability. This does not include loses incurred
before the IPO. Our results, taken together with other studies
on the costs to develop drugs, show that most firms are increas-
ingly spending billions of dollars on new drug and therapeutic
development, with little profit to show for it.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at https://doi.org/10.1016/j.drudis.2018.06.
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